MauiDerm NPA Summer 2021 (hybrid)

Tuesday, June 22, 2021, 11:34 AM - Saturday, June 26, 2021, 5:00 PM, The Broadmoor, 1 Lake Ave

AMA PRA Category 1 Credits™ (30.25 hours), AMA PRA Category 1 Credits™ Designated (30.25 hours)


Please join us at the 9th Annual Maui Derm NP+PA Summer 2021 meeting which will be held June 23-26, 2021 at the Broadmoor Hotel in Colorado Springs, Colorado. The Summer meeting is part of our “On the Road” program that brings Maui Derm NP+PA to inspired locations throughout the U.S. exclusively for Nurse Practitioners and Physician Assistants who already provide dermatologic healthcare.

This four-day meeting will feature a one day “Special Pre-Conference Day” held on June 23, 2021 followed by our three day meeting.

You will learn some alternate ways to handle common problems and emerging methods to tackle those tough cases. Our world-class faculty have geared their presentations toward providing pearls you can put to use your first day back at work! Disease pathogenesis, differential diagnoses, therapeutic mechanisms of action, treatment algorithms and outcome measures are incorporated into case based discussions. Ample time for Q&A has been built into the program. The exquisite setting of the Broadmoor Hotel offers a perfect setting for interactions with your colleagues, society leadership and speakers.

We encourage you to join us for what promises to be an exceptional educational opportunity and look forward to meeting you in Colorado Springs.

To register for either MauiDerm Live or MauiDerm Connect, please go to:

https://mauiderm.com/maui-derm-nppa-summer-2021-overview-2/#toggle-id-3

Please see detailed fees on the website above.  

 

 

1. Review the pathogenesis of various dermatological conditions such as infectious diseases, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, pruritus, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, connective tissue disorders, granulomatous disorders of the skin, connective tissue diseases, hair and nail disorders, leg ulcers, oral lesions and life-threatening dermatoses such as TEN in order to accurately diagnose and improve upon the management of these conditions in patients
2. Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
3. Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
4. Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in derma- tology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell and B-cell targeted therapies, anti-IL-12/23, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL-4 receptor and IL-13 antibodies, systemic retinoids, methotrexate, cyclosporine, neurokinin-1 receptor antagonists, systemic and topical acne/rosacea therapies, oral and topical antibiotics, antifungals, anti-viral therapies, wound healing agents, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod, diclofenac, tirbanibulin, photodynamic therapy, hedgehog pathway inhibitors, rituximab, BRAF/MEK inhibitors, CTLA-4 and PD-1/PDL-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, deoxycholic acid and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
5. Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
6. Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic and Medical Dermatology.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 30.25 AMA PRA Category 1 Credits ™.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

The Broadmoor 1 Lake Ave, Colorado Springs, CO 80906/virtual platform 

Make reservations at: https://mauiderm.com/maui-derm-nppa-summer-2020-hotel-reservations-2-2-2-2/

No faculty are available for this activity at this time.